hypertensive disorders in prev 1 ious pregnancy. Other factors have lesser risks e.g. obesity, age, null parity, family history of hypertensive disorders of pregnancy or a blood pressure at the higher end of normal range for age 5, 6 . The aims of management of hypertensive disorders of pregnancy are prevention of maternal & fetal complications and to continue the pregnancy up to term if possible to ensure a safe delivery for both mother & fetus.
is no longer the criteria and has not proved to be a good prognostic indicator 7 .
Gestational hypertension: Hypertension without proteinuria, developing after 20 weeks of gestation , during labour , or the puerperium in a previously normotensive nonproteinuric woman.
Preeclampsia: Hypertension associated with proteinuria greater than 0.3 g/L in a 24 -hour urine collection or 1 + by qualitative urine examination, after 20 weeks of gestation.
Eclampsia: Convulsion occurring in a patient with preeclampsia is known as eclampsia.
Chronic hypertension: It is defined as hypertension present before the 20 th week of pregnancy or that present before pregnancy. Hypertension should be documented on at least two occasions measured at least 4 hours apart 8 .
Chronic hypertension with superimposed preeclampsia: It is defined as proteinuria developing for first time during pregnancy in a woman with known chronic hypertension.
Management of gestational hypertension
Gestational hypertension is the most frequent hypertensive condition of pregnancy with a prevalence of 6 -15% in nulliparae and 2-4% in multiparae 9, 10 . On management point of view patients may be categorized into mild (BP 140/90-149/99 mm Hg), moderate (BB150/100-159/109 mm Hg) and severe hypertension (BP 160/110 mm Hg or more) 11 . Women with gestational hypertension require an evaluation whether there is any significant risk factors for poor pregnancy outcome (Box-I).
Box-I: Criteria to identify high -risk women with gestational hypertension
• Blood pressure 150/100 or more
• Gestational age less than 30 weeks
•
Evidence of end organ damage(elevated serum creatinine, liver enzymes, LDH, decreased platelet count)
• Oligohydramnios
• Fetal growth restriction 
Management of preeclampsia
Preeclampsia is a disease that originates and propagates through the placenta and delivery is the ultimate remedy. Preeclampsia is mild or severe depending on the level of BP and on the presence of features of end organ damage. Preeclampsia is mild if BP is <160 /110mm of Hg and there is no sign symptoms associated with severe preeclampsia described in Box-II 2
Box-II: Criteria of severe preeclampsia
• Systolic BP is > 160 mm of Hg and diastolic BP is > 110 mm of Hg.
• Proteinuria of >5 g in a 24 hours urine specimen or 3+ or more on two random urine samples collected at least 4 hours apart
• Oliguria or <500 ml in 24 hours
• Cerebral or visual disturbances
• Pulmonary edema or cyanosis
• Epigastric or right upper quadrant pain
• Impaired liver function.
• Thrombocytopenia
Fetal growth restriction
The patient is usually hospitalized upon diagnosis to ensure bed rest, because this diminishes the possibility of convulsion and enhances the chance of fetal survival. But absolute prolonged bed rest is avoided to prevent deep vein thrombosis. Actual management of preeclampsia depends on the severity of hypertension and gestational age at diagnosis .If the gestational age is e" 37 weeks patient should be delivered as there is no benefit in continuing the pregnancy. However patient with mild preeclampsia and gestational age <37weeks who can be relied on to follow the physician's instruction may be treated as outpatients. A typical home regime includes bed rest, daily urine dipstick measurement of proteinuria and BP monitoring. Patients are advised to attend antenatal clinic at least twice weekly for fetal heart rate testing and 24-hour urine protein measurement. Patients are warned of the danger signals such as severe headache, epigastric pain and visual disturbances and on occurrence of these signals with increasing BP and proteinuria hospitalization is advised.
After hospitalization, BP is measured 4 hourly. Urine dipstick measurement of proteinuria and weight is checked daily. Serum creatinine and twenty-four hour urinary protein are measured twice weekly. Liver function test, uric acid, serum electrolytes and serum albumin are measured on admission and weekly. Ultrasound examination is done on admission and every two weeks to determine gestational age, estimated fetal weight (EFW) and amniotic fluid volume. Abnormal fetal biometry demands evaluation with uterine, umbilical and middle cerebral artery Doppler study and repeated weekly. Non stress test (NST) is done twice weekly. Expectant management is continued up to 37 weeks if fetal and maternal condition is stable. The antihypertensive of choice is oral labetalol in the dose of 100-400 mg every 8-12 hours.
In case of severe preeclampsia, the obstetric management will depend on the gestational age at the time of diagnosis. Some authorities consider delivery as the definitive treatment regardless of gestational age, although delivery may not be optimal for a fetus that is extremely premature. If a patient presents with severe preeclampsia before 34 weeks' gestation but appears to be stable and the fetal condition is reassuring, expectant management may be considered only in a tertiary center.
All of these patients must be evaluated in a labor and delivery unit for 24 hours before a decision for expectant management can be made. It is recommended that treatment for severe hypertension should be started promptly aiming for a gradual and sustained lowering of BP. Drugs for the treatment of very high BP in pregnancy have been the subject of Cochrane review which concluded that no good evidence exists that any short acting antihypertensive is better than other 17 .Several rapidly acting agents are available to control severe hypertension ( Table-I ).
There is an important concern that a precipitous fall in BP particularly after intravenous hydralazine, may impair placental perfusion resulting in fetal distress. This can be prevented by co administration of a small bolus of fluid e.g.250 ml of normal saline at the time of administration of antihypertensive therapy 18 . Continuous CTG monitoring should be considered in this situation, particularly when there is evidence of existing fetal compromise. The concurrent administration of longer acting oral agents ( Table-II) can achieve a sustained BP lowering effect. The most important consideration in choice of antihypertensive agent is that the institute has experience and familiarity with that agent. It is recommended that protocols for the management of severe hypertension should be readily accessible in all obstetrics units.
Magnesium sulphate is the medication most commonly used for the prevention of seizure in patients with severe preeclampsia. There is good evidence indicating the effectiveness of magnesium sulphate.
In the Magpie Trial 26% of the participants had severe preeclampsia, the incidence of eclampsia was 2.7% in the placebo group versus 1.1% in Magnesium sulphate group 19 .
Women with severe preeclampsia who are managed expectantly must be delivered under the following circumstances (Box-III) 20
Box-III: Criteria for termination of pregnancy in severe preeclampsia
• Nonreassuring fetal heart status • Uncontrollable BP
• Oligohydramnios, with amniotic fluid index (AFI) of less than 5 cm
• Severe intrauterine growth restriction in which the estimated fetal weight is less than 5%
• Oliguria (< 500 mL/24 h)
• Serum creatinine level of at least 1.5 mg/dL
• Pulmonary edema
• Shortness of breath or chest pain with pulse oximetry of < 94% on room air
• Headache that is persistent and severe
• Right upper quadrant tenderness • Development of HELLP syndrome
In most cases of severe preeclampsia before 34 weeks, induction of labour is unsuccessful and approximately 80% of these women need caesarean delivery 21 .In case of fetal growth restriction the incidence of abnormal FHR monitoring pattern during labour is high, so caesarean section is preferable. Regional anaesthesia is preferred to general anaesthesia (GA) for cesarean section, especially airway problems including laryngeal oedema may be increased [22] [23] [24] . However well-conducted GA is also suitable and may be indicated in the presence of severe fetal compromise, pulmonary edema, haemodynamic instability,risk of intraspinal haematoma (e.g. placental abruption, severe thrombocytopenia) or after eclampsia where altered consciousness or neurological deficits persist 25, 26 .
Management of eclampsia
Eclampsia can occur during the antepartum, intrapartum, and postpartum periods. Ninety percent of eclampsia cases occur after 28 weeks' gestation. 27 .The first step in the management of eclampsia is the treatment of convulsion. To decrease the risk of aspiration the patient should be placed in the lateral position. The bedside rails should be elevated to avoid maternal injury. Tongue bite should be prevented by inserting a padded tongue blade between the patient's teeth. Supplemental oxygen by mask should be started at 8-10 L/minute. Magnesium sulphate is the most commonly used anticonvulsant agent worldwide. Cochrane reviews showed that in women with eclampsia magnesium sulphate had statistically significantly better results than previously used drugs like diazepam, phenytoin and lytic cocktail in preventing maternal death and recurrence of convulsion [28] [29] [30] . Another effective medication in the management of eclamptic patient is nimodipine, a calcium channel blocker which causes selective vasodilatation of the brain vasculature. It is of particular benefit when the mechanism of seizure is cerebral vasoconstriction which is seen in those eclamptic women with normal or mildly elevated systemic blood pressure. Nimodipin is given in doses of 60 mg orally every 4-6 hours. The Cochrane review comparing nimodipine with magnesium sulphate showed that women treated with nimodipine were statistically significantly less likely to develop persistent high blood pressure than those treated with magnesium sulphate 31 . Magnesium sulphate should be continued for a minimum period of 24 hours following the last convulsion.
Severe hypertension must be addressed after controlling convulsion. The goal is to maintain BP between 140/90 and 160/110 mm Hg. Labetalol or hydralazine can then be administered intravenously for control of BP. Recommended doses of IV bolus of hydralazine (5-10 mg) or labetalol (20-40 mg The HELLP syndrome is a recognized complication of preeclampsia and eclampsia of pregnancy, occuring in 25% of these pregnancies. It is a syndrome having a combination of "H" for hemolysis, "EL" for elevated liver enzymes, and "LP" for low platelet count .It is a variant of severe preeclampsia where hypertension is less marked but there is severe involvement of liver and coagulation system and may lead to liver failure and severe bleeding. In a patient with possible HELLP syndrome, some specific blood tests are performed e.g. a full blood count, liver enzymes, renal function and electrolytes and coagulation studies. Often, fibrin degradation products (FDPs) are determined, which can be elevated. D-dimer is a more sensitive indicator of subclinical coagulopathy and may be positive before coagulation studies are abnormal. A positive D-HYPERLINK "http://en.wikipedia.org/wiki/Ddimer"dimer test in the presence of preeclampsia has recently been reported to be predictive of patients who will develop HELLP syndrome. 32 Lactate HYPERLINK "http://en.wikipedia.org/wiki/Lactate_dehydrogenase "dehydrogenase is a marker of hemolysis and is elevated (>600 U/liter).The only effective treatment is prompt delivery of the baby .The DIC is treated with fresh frozen plasma to replenish the coagulation proteins, and the anemia may require blood transfusion. In mild cases, corticosteroids and antihypertensives (labetalol, hydralazine, nifedipine) may be sufficient. Intravenous fluids are generally required. Hepatic hemorrhage can be treated with embolization if there is life-threatening bleeding.
Managemant of Chronic Hypertension
Chronic hypertension occurs in up to 22% of women of childbearing age, with the prevalence varying according to age, race, and body mass index (BMI 
Management of Chronic Hypertension With Superimposed Preeclampsia
Preeclampsia superimposed on chronic hypertension is characterized by new-onset proteinuria (or by a sudden increase in the protein level if proteinuria is already present), an acute increase in the level of hypertension (assuming proteinuria already exists), or development of the HELLP syndrome 36 .
Currently there is no single reliable, cost-effective screening test for preeclampsia. 36 The serum uric acid level was once used as an indicator of preeclampsia but has been found to lack sensitivity and specificity as a diagnostic tool. However, an elevated serum uric acid level may be of some use in identifying pregnant women with chronic hypertension who have an increased likelihood of having superimposed preeclampsia 37 . A baseline laboratory evaluation should include hepatic enzyme level, platelet count, serum creatinine level and urinary total protein measurement. Urinary protein-to-creatinine ratios predict the 24-hour urine total protein level and may provide a faster, simplified method of estimating proteinuria, providing that the protein values are less than 1 g in 24 hours 38 . In women who have preeclampsia with no suspected progression, all laboratory tests should be conducted weekly 36, 39 . If progression of eclampsia is suspected, the tests should be repeated more frequently.
Once the diagnosis of superimposed preeclampsiaeclampsia is made the treatment will be accordingly. Magnesium sulfate should be used for women with superimposed severe preeclampsia to prevent seizures. Delivery should be considered in all women with superimposed severe preeclampsia at or beyond 34 weeks of gestation and in women with mild superimposed preeclampsia at or beyond 37 weeks of gestation. Women with preeclampsia should be counseled about future pregnancies. In nulliparous women with preeclampsia before 30 weeks of gestation, the recurrence rate for the disorder may be as high as 40 percent in future pregnancies. Multiparous women have even higher rates of recurrence 39 .
Post-Partum Care in Hypertensive Women
Patients with severe preeclampsia should be monitored closely for at least 48 hours after delivery because they are at risk for hypertensive encephalopathpy, pulmonary oedema and renal failure.
However,women who experienced hypertension during pregnancy may be normotensive immediately after the birth, but then become hypertensive again in the first postnatal week. The need to obtain hypertensive control may delay discharge. Methyldopa should be avoided because of the risk of postnatal depression. First line antihypertensive agent is atenolol, plus nifedipine or an ACE inhibitor if another agent is required. Women with gestational hypertension, or pre-eclampsia, are usually able to stop all antihypertensives within six weeks post partum. Those with chronic hypertension can resume their prepregnancy drugs. Diuretics, however, are usually avoided if the woman wishes to breast feed because of increased thirst. Proteinuria in pre-eclamptic women will usually remit by three months post partum, in the absence of any underlying renal abnormality 40 . Persistent proteinuria requires further renal investigation. Women who have become normotensive after suffering from preeclampsia or eclampsia can use standard dose oral contraceptive pill safely 41 .
